Good point. But bear in mind Alan is on record at the AGN advising investors not to read too much into Avactas RNS comments about disease free pogression. Go figure?
The ‘we’re too expensive’ line was moronic. Didn’t need said in response to the question. The ‘don’t read too much into the disease not progressed’ line in the RNS.
Couldnt agree more. I cringed when I heard the CEO come out with these comments. He iw supppsed be a salesman championing Avact
Largo, if its not useful to you i suggest you click on the filter button or simply skim over. There is no need to be rude. We are all patiently waitng for Alan to announce the MTD.